T
Taysha Gene Therapies, Inc. (TSHA)
4.07
0.00 (0.00%)
Get all premium features to the best stock analysis tool
4.07
0.00 (0.00%)
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
| Name | Position |
|---|---|
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program |
| Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations |
| Mr. Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer |
| Mr. Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary |
| Mr. Sean McAuliffe | Chief Business Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-19 | 10-K | tsha-20251231.htm |
| 2026-01-06 | S-8 | d20072ds8.htm |
| 2025-11-04 | S-3ASR | d42113ds3asr.htm |
| 2025-10-16 | 8-K | d35488d8k.htm |
| 2025-10-09 | 8-K | d949053d8k.htm |
| 2025-10-02 | 8-K | d61846d8k.htm |
| 2025-08-12 | 10-Q | tsha-20250630.htm |
| 2025-06-03 | 8-K | d843671d8k.htm |
| 2025-05-29 | 8-K | d948981d8k.htm |
| 2025-05-28 | 8-K | d904503d8k.htm |
| Mr. Sean P. Nolan | CEO & Chairman |
| Ms. Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer |
| Ms. Tracy M. Porter SPHR | Chief People Officer |